Rhumbline Advisers I Mab Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in I Mab stock. As of the latest transaction made, Rhumbline Advisers holds 333 shares of IMAB stock, worth $1,688. This represents 0.0% of its overall portfolio holdings.
Number of Shares
333
Previous 361
7.76%
Holding current value
$1,688
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding IMAB
# of Institutions
41Shares Held
14.2MCall Options Held
10.2KPut Options Held
0-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$30.3 Million0.6% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$21.1 Million3.04% of portfolio
-
Candriam S.C.A.1.13MShares$5.74 Million0.02% of portfolio
-
Sg Americas Securities, LLC876KShares$4.44 Million0.01% of portfolio
-
International Biotechnology Trust PLC London, X0310KShares$1.57 Million0.14% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $421M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...